Global Favipiravir Tablets Market Growth 2025-2031

The global Favipiravir Tablets market size is predicted to grow from US$ 2394 million in 2025 to US$ 3159 million in 2031; it is expected to grow at a CAGR of 4.7% from 2025 to 2031.

Favipiravir is an antiviral drug which has been licenced in Japan since 2014 to treat influenza. It works by inhibiting a viral enzyme called RNA polymerase, preventing viral replication within human cells. This viral enzyme is common to several viruses, including SARS-CoV-2, which causes COVID-19. The drug has shown positive results against SARS-CoV-2 in laboratory and animal studies, with small pilot studies in humans demonstrating some benefit in reducing symptoms and the duration of illness.

LP Information, Inc. (LPI) ' newest research report, the “Favipiravir Tablets Industry Forecast” looks at past sales and reviews total world Favipiravir Tablets sales in 2024, providing a comprehensive analysis by region and market sector of projected Favipiravir Tablets sales for 2025 through 2031. With Favipiravir Tablets sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Favipiravir Tablets industry.

This Insight Report provides a comprehensive analysis of the global Favipiravir Tablets landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Favipiravir Tablets portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Favipiravir Tablets market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Favipiravir Tablets and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Favipiravir Tablets.

This report presents a comprehensive overview, market shares, and growth opportunities of Favipiravir Tablets market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Brand Drug
Generic Drug

Segmentation by Application:
Influenza Viruses
COVID-19
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
ChemRar Group
Glenmark
Fujifilm
Dr. Reddy
R-Pharma
Cipla
Lupin
Sun Pharma
Hisun Pharm

Key Questions Addressed in this Report

What is the 10-year outlook for the global Favipiravir Tablets market?

What factors are driving Favipiravir Tablets market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Favipiravir Tablets market opportunities vary by end market size?

How does Favipiravir Tablets break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.